| . | Phase I (n= 18) . | Phase II (n= 20) . |
|---|---|---|
| Age (years) | 62.4 ± 10 | 61.9 ± 13 |
| Gender (male/female) (%) | 76/24 | 65/35 |
| Drugs (%) | ||
| Beta-blockers | 59 | 65 |
| Cardiac glycosides | 35 | 25 |
| Other antiarrhythmic drugs | 12 | 25 |
| Type of atrial fibrillation (%) | ||
| Paroxysmal | 6 | 15 |
| Persistent | 35 | 40 |
| Long-standing persistent | 59 | 45 |
| . | Phase I (n= 18) . | Phase II (n= 20) . |
|---|---|---|
| Age (years) | 62.4 ± 10 | 61.9 ± 13 |
| Gender (male/female) (%) | 76/24 | 65/35 |
| Drugs (%) | ||
| Beta-blockers | 59 | 65 |
| Cardiac glycosides | 35 | 25 |
| Other antiarrhythmic drugs | 12 | 25 |
| Type of atrial fibrillation (%) | ||
| Paroxysmal | 6 | 15 |
| Persistent | 35 | 40 |
| Long-standing persistent | 59 | 45 |
| . | Phase I (n= 18) . | Phase II (n= 20) . |
|---|---|---|
| Age (years) | 62.4 ± 10 | 61.9 ± 13 |
| Gender (male/female) (%) | 76/24 | 65/35 |
| Drugs (%) | ||
| Beta-blockers | 59 | 65 |
| Cardiac glycosides | 35 | 25 |
| Other antiarrhythmic drugs | 12 | 25 |
| Type of atrial fibrillation (%) | ||
| Paroxysmal | 6 | 15 |
| Persistent | 35 | 40 |
| Long-standing persistent | 59 | 45 |
| . | Phase I (n= 18) . | Phase II (n= 20) . |
|---|---|---|
| Age (years) | 62.4 ± 10 | 61.9 ± 13 |
| Gender (male/female) (%) | 76/24 | 65/35 |
| Drugs (%) | ||
| Beta-blockers | 59 | 65 |
| Cardiac glycosides | 35 | 25 |
| Other antiarrhythmic drugs | 12 | 25 |
| Type of atrial fibrillation (%) | ||
| Paroxysmal | 6 | 15 |
| Persistent | 35 | 40 |
| Long-standing persistent | 59 | 45 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
